UNCY
$6.98
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being ...
Recent News
Companies Like Unicycive Therapeutics (NASDAQ:UNCY) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Retail investors who hold 48% of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) gained 23%, institutions profited as well
Key Insights Unicycive Therapeutics' significant retail investors ownership suggests that the key decisions are...
When Will Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Turn A Profit?
We feel now is a pretty good time to analyse Unicycive Therapeutics, Inc.'s ( NASDAQ:UNCY ) business as it appears the...
Is Unicycive Therapeutics (NASDAQ:UNCY) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Retail investors are Unicycive Therapeutics, Inc.'s (NASDAQ:UNCY) biggest owners and were hit after market cap dropped US$28m
Key Insights The considerable ownership by retail investors in Unicycive Therapeutics indicates that they collectively...